BCIQ Profiles

Company Profile Report
0414 QT Reg
BioCentury & Getty Images

Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

Apr 15, 2021 | 1:19 AM GMT

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is discontinuing treatment with ICOS agonist feladilimab (GSK3359609) in two Phase II trials for metastatic head and neck squamous cell carcinoma following a recommendation by the independent

Read the full 572 word article

How to gain access

Continue reading with a
two-week free trial.